Stay updated on First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.

Latest updates to the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page
- Check6 days agoChange DetectedNew date stamps and results-posting status were added (e.g., 'No Results Posted' on 2026-03-03), and older entries were removed. The overall study details, eligibility criteria, and planned interventions remain unchanged.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange Detected- Revision: v3.4.2 has been added. The government funding notice and Revision: v3.4.1 banner have been removed; no study content or eligibility information was changed.SummaryDifference0.3%

- Check34 days agoChange DetectedResults status updated from No Results Posted to Results Submitted, and the page revision shows Revision: v3.4.1. A government-funding status notice about NIH operations is also displayed.SummaryDifference0.3%

- Check41 days agoChange DetectedUI updates include showing a glossary and new metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, Revision: v3.4.0) along with the removal of older labels (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).SummaryDifference0.2%

- Check56 days agoChange DetectedPage footer revision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check77 days agoChange DetectedThe locations section has been expanded to list more trial sites across the US, Canada, Australia, Europe, and Asia, organized by region. This makes it easier for potential participants to find a nearby site and assess eligibility.SummaryDifference1%

Stay in the know with updates to First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.